ECOBIOTECH PHARMA
Founded 2015
About ECOBIOTECH PHARMA
Ecobiotech Pharma is an India-based proprietary manufacturing and export company specializing in quality chemical products, hygiene solutions, water purification systems, and consumer beverages. Headquartered in Bhopal, Madhya Pradesh, Ecobiotech Pharma operates state-of-the-art production and quality assurance facilities to serve both domestic and international markets. Its traditional product portfolio includes disinfectants, cleaning solutions, air fresheners, and water purification tablets trusted by industries, NGOs, and water treatment facilities globally. ∩┐╝ In addition to its core sanitization and purification offerings, Ecobiotech Pharma manufactures,owns and markets BOZO, a specialized purified and mineral-balanced blended water product designed to enhance the drinking experience of premium alcoholic beverages such as whisky, vodka, rum, and gin. Positioned as a lifestyle and premium beverage accessory, BOZO supports consistent taste and aroma preservation for spirits and cocktails. BOZO – Purified & Mineral-Blended Water for Spirits and Cocktails (premium water brand) ∩┐╝ • NEEMOLA – Disinfectant Floor Cleaner ∩┐╝ • BIOCLEAN – Surface & Floor Disinfectant ∩┐╝ • CLASSPIC – Toilet Cleaner ∩┐╝ • PIXEL – Glass Cleaner ∩┐╝ • SANITIZO – Hand Sanitizers (Gel & Hand Rub) ∩┐╝ • GO AIR – Air Fresheners ∩┐╝ • NADCC Tablets – Water Purification & Disinfection Tablets ∩┐╝ Business Model: Ecobiotech Pharma combines B2B manufacturing and export operations with B2C and B2B2C brand marketing (via products like BOZO). It serves institutional buyers (hospitals, water utilities, food processing plants) as well as lifestyle and hospitality segments for premium beverage water.
Company Facts
- Founded: 2015
- Operating status: Operating
- Company type: For Profit
- IPO status: Private
- Employees: 1 – 10
- Website: ecobiotechpharma.com
- Phone: +91 9111115450
Canonical: https://fsome.com/organization/ecobiotech-pharma-8433906 · For the full interactive profile (charts, investors, team, acquisitions, press), please enable JavaScript.